Merck to Buy Australian Viral Immuno-oncology Firm for $394 Million Merck to Buy Australian Viral Immuno-oncology Firm for $394 Million

U.S. drugmaker Merck& Co, already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics for 502 million Australian dollars ($394 million) to expand its pipeline in the sector.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news